Current role
Lisa von Moltke
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Lisa von Moltke
Earlier roles on record: Board Member at Tvardi Therapeutics, Inc. (TVRD) until April 15, 2025. Tvardi Therapeutics, Inc. reported in an 8-K filed April 15, 2025 that Lisa von Moltke resigned as director, effective April 15, 2025. The proxy statement of Zenas BioPharma, Inc. reports total compensation of $3,499,447 for Lisa von Moltke in fiscal 2025, including a base salary of $411,667. Disclosed compensation is on record for 4 fiscal years. Lisa von Moltke has spoken on 1 earnings call across 1 company, most recently for Seres Therapeutics, Inc. on March 13, 2025.
“In accordance with the Merger Agreement, immediately prior to and effective upon the closing of the Merger, Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company's board of directors and committees of the board of directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Zenas BioPharma, Inc. (ZBIO)
Proxy statement
CurrentStart not stated–present
-
Start not stated–2025-04-15
-
Seres Therapeutics, Inc. (MCRB)
Proxy statement
Start not stated–2025-03-14
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Zenas BioPharma, Inc.
Other people whose current roles at this company are on record from its filings.
- Leon O. Moulder CEO
- Jennifer Fox CFO
- Joseph L. Farmer COO
- Christy J. Oliger Board Member
- Hongbo Lu Board Member
- Hongbo Lu, Ph.D. Board Member
- Jake Nunn Board Member
- James Boylan Board Member
- John Orloff Board Member
- Leon O. Moulder, Jr. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Zenas BioPharma, Inc. (ZBIO) | Head of Research and Development and Chief Medical Officer | $411,667 | $3,499,447 |
| 2024 | Seres Therapeutics, Inc. (MCRB) | Executive Vice President and Chief Medical Officer | $515,000 | $1,270,353 |
| 2023 | Seres Therapeutics, Inc. (MCRB) | Executive Vice President and Chief Medical Officer | $515,000 | $1,571,141 |
| 2022 | Seres Therapeutics, Inc. (MCRB) | Executive Vice President and Chief Medical Officer | $490,000 | $1,734,614 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.